Investor Presentaiton

→ US Market Large, Growing and Underpenetrated Market Estimated Net Bronchiectasis prevalence, DIAGNOSED¹ ~127K HFCWO ADOPTED¹ ~824K U.S. BE Diagnosed¹ Estimated HFCWO bronchiectasis penetration, treated population¹ Estimated bronchiectasis prevalence, UNDIAGNOSED² 4.1 million U.S. Undiagnosed² ¹Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database 2Internal company estimates derived from GUIDEHOUSE 2023 literature review and 2023 CDC NHANES data smartvest AIRWAY CLEARANCE SYSTEM Bronchiectasis HFCWO penetration ~15%¹ Diagnosed BE population growing at ~12% annually¹ ELECTROMED, INC. 16

View entire presentation